The Only Cancer-Specific, Non-PSA Blood Test That May Aid in the Assessment of Risk for the Presence of Prostate Cancer
APIFINY® technology is based on the measurement of eight prostate-cancer-specific autoantibodies in human serum. These autoantibodies are produced and replicated (amplified) by the immune system in response to the presence of prostate-cancer cells. The autoantibodies are stable and, because of their amplification, are likely to be abundant and easy to detect, especially during the early stages of cancer. The use of APIFINY results may supplement other information about prostate-cancer risks, and may therefore aid in earlier diagnosis of prostate cancer and potentially increase survival rates.
Given the complexity of cancer-risk assessment, obtaining additional biological information may provide insight to better inform an important clinical decision such as an initial or repeat biopsy.
- APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.
- APIFINY measures specific biological markers known to be associated with an immune system response to prostate cancer, which may provide you with additional insight to support a clinical decision.
- Combined with existing patient information and your clinical experience, APIFINY may aid in the assessment of prostate-cancer risk.
Limitations of the PSA test for the early detection of prostate cancer have spurred research into other biological markers to support improved risk assessment. The discovery that patients with cancer produce detectable autoantibodies against antigens in their tumors suggests that these biomarkers could have diagnostic and prognostic value.1
APIFINY is one such prostate-cancer-specific blood test that does not rely on PSA values. The technology measures the body’s immune-system response to cancer, which may help your practice better assess risk for the presence of prostate cancer.
1. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353(12):1224-35.